Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells


Pharmaceutical Chemistry Journal, vol.53, no.11, pp.1036-1046, 2020 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 11
  • Publication Date: 2020
  • Doi Number: 10.1007/s11094-020-02119-9
  • Journal Name: Pharmaceutical Chemistry Journal
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE
  • Page Numbers: pp.1036-1046
  • Keywords: MCF-7, A549, benzimidazole, anticancer activity, apoptosis, cytotoxicity, BIOLOGICAL EVALUATION, MOLECULAR DOCKING, DERIVATIVES, SCAFFOLD


© 2020, Springer Science+Business Media, LLC, part of Springer Nature.A series of benzimidazole-piperazine hybrids (14 – 37) were designed, synthesized and evaluated for their cytotoxic activity against human lung (A549) and breast (MCF-7) cancer cell lines. Preliminary evaluation revealed that most of these hybrid molecules (i.e., 16 – 25) exhibited noteworthy and preferential antiproliferative effect against human lung cancer (A549) with IC50 values of 2.8 – 7.8 μM. Among the synthesized molecules, compound 17 showed the most balanced cytotoxic effect against lung (A549) and breast (MCF-7) cancer cells with IC50 values of 5.4 and 4.2 μM, respectively. To explore the mechanistic aspects fundamental to the observed activity, further biological studies of compounds 16, 17 and 22 were carried out. In addition, these compounds induced PARP-1 cleavage and caspase 7 activation, caused morphological changes such as bleb formation in the treated cells, and significantly increased the nuclear fragmentation. Taken all together, our findings indicate that cytotoxic activities of newly synthesized benzimidazole-piperazine hybrids are mediated through the apoptotic cell death induction. These benzimidazole derivatives have the potential for further development as anticancer agents.